Mashup Score:17
alliedhealth-beaumonthospital.icims.comLung Health Check Programme Manager in Dublin | Careers at Beaumont Hospital - 6 days
Mashup Score:17
Twitter Feed: Jarushka Naidoo
Mashup Score:11
JTO Clinical and Research ReportsDurvalumab maintenance therapy following definitive concurrent chemoradiotherapy (CRT) is the standard treatment modality for stage III non-small cell lung cancer (NSCLC). Although severe treatment-related...
-
Recovery from treatment-related lymphopenia (TRL) after chemoRT/on durva affects stage III NSCLC outcomes @JTOonline: - 151pts, 27% TRL recovery, 73% not - mPFS 21.9m v NR (p=0.018) favoring TRL grp - ⬆️pre-CRT ALC & TRL assoc w ⬆️PFS @Oncoalert #LCSM https://t.co/QBIJXPRz1D - view on twitter
More coverage:
#lcsm
Mashup Score:9
PubMedSevere RIL compromises survival benefits from durvalumab after CCRT for NSCLC. Measures to mitigate RIL after CCRT may be warranted to enhance the benefit...
-
@JTOonline Builds on a growing body of evidence that RT induced lymphopenia matters in the context of IO for stage III NSCLC, further data in this setting published @JTOonline @IASLC by @PercyLeeMD et al below: https://t.co/pR5WG2VFh9 - view on twitter
Mashup Score:7
Journal of Thoracic OncologyIn KRAS-mutant non-small lung cancer (NSCLC), co-occurring alterations in LKB1 confer a negative prognosis compared to other mutations such as TP53. LKB1 is a...
-
HDAC6i is a metabolic vulnerability in KRAS/LKB1 (KL) nsclc models: - metabolic pathways in KL v KP (kras/p53) assessed in vitro+in vivo - ⬆️efficacy w glutaminase inhibtn in KL models Great 🇮🇪🇺🇸 collaboration @DrCDowling @IrishLungCancer @RCSI_Irl #LCSM https://t.co/2hXXW9xXmM - view on twitter
More coverage:
#lcsm
Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2) alterations are found in approximately 2-5% of non-small cell lung cancers (NSCLCs); the majority are...
-
ZENITH20 Ph 2 Trial Poziotinib in HER2mt NSCLC @JTOonline: - 80pts - ORR 39%; DCR 73%; mPFS 5.6m - TRAEs: rash, stomatitis, diarrhea - G778_P780dupGSP HER2 mtn had ⬆️ORR 71% Early signal that mtn subtype matters in HER2mt NSCLC w pozi @OncoAlert #LCSM https://t.co/GXaoXlhOsb - view on twitter
More coverage:
#lcsm
Mashup Score:1
Daily ReporterDurable efficacy of amivantamab in mutated NSCLC - 15 hours
Mashup Score:1
Updated results from the CHRYSALIS trial in pretreated NSCLC with EGFR Exon 20 insertion...
-
#ELCC Day 1 Highlight: Amivantamab long-term outcomes + biology in EGFR exon20ins+ NSCLC: - 48% pts have clinical benefit at 1yr - 47.2% pts alive at 2yrs - Baseline ctDNA alteratns in RAS/RAF/MEK assoc with less time on tx @myESMO @Piuchagarrido #LCSM https://t.co/8bsGk75lvp https://t.co/8bsGk75lvp - view on twitter
...
-
RT @andersgranholm: #MethodMonday 12: Covariate adjustment in RCTs https://t.co/mW2n8mueWq This week includes FDAs draft recommendations fo… - view on twitter
More coverage:
#methodmonday
Contact...
🔥Job alert🔥 As part of @EuroRespSoc #SOLACE consortium funded by #EU4Health, we will be running a 'Lung Health Check' pilot on early detection of NSCLC Join us as the Lung Health Check Program manager!👇 @CancerCentreIre @RCSI_Research @danennis100 https://t.co/PVe8T8gQuB - view on twitter